ReviewTherapeutics and clinical risk management2020

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date.

Sarah Bassiony et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.